Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie-Reference-Cited by-同舟云学术

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Published:2008-11 Issue:11 Volume:19 Page:1882-1887
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Al-Batran S.-E.,Hartmann J.T.,Hofheinz R.,Homann N.,Rethwisch V.,Probst S.,Stoehlmacher J.,Clemens M.R.,Mahlberg R.,Fritz M.,Seipelt G.,Sievert M.,Pauligk C.,Atmaca A.,Jäger E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/11/1882/511611/mdn403.pdf

Reference17 articles.

1. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer;Glimelius;Ann Oncol,1997

2. Advances in the treatment of patients with gastric adenocarcinoma;Foukakis;Acta Oncol,2007

3. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group;Van Cutsem;J Clin Oncol,2006

4. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group;Ajani;J Clin Oncol,2007

5. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group;Ajani;J Clin Oncol,2007

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hexokinase 2 as an independent risk factor for worse patient survival in esophageal adenocarcinoma and as a potential therapeutic target protein: A retrospective, single‑center cohort study;Oncology Letters;2024-08-13

2. Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials;Current Medical Research and Opinion;2024-07-13

3. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study;Current Medical Research and Opinion;2024-06-22

4. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma;JAMA Oncology;2024-06-01

5. Adenokarzinome des ösophagogastralen Übergangs;Allgemein- und Viszeralchirurgie up2date;2024-06